文献速递乳腺癌

I-SPY2试验:新辅助治疗后pCR与3年EFS和DRFS的个体水平关联分析

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

I-SPY2平台试验纳入950例可手术的2-3期乳腺癌女性,评估新辅助治疗后病理完全缓解(pCR)与3年无事件生存(EFS)及无远处复发生存(DRFS)的关联。中位年龄49岁,34.7%达到pCR,pCR者3年EFS和DRFS均为95%,pCR对比非pCR的EFS风险比0.19(95%CI 0.12-0.31),DRFS风险比0.21(95%CI 0.13-0.34),各分子亚型相似。

要点

  • 新辅助治疗后达到pCR者3年EFS和DRFS均为95%。
  • pCR对比非pCR的EFS风险比0.19,DRFS风险比0.21。
  • 各分子亚型及治疗方案的HR相似,EFS为0.14-0.18,DRFS为0.10-0.20。

核心结论

  • 无论分子亚型或治疗 regimen(包括9种新药联合方案),新辅助治疗后达到pCR意味着复发率约降低80%。

研究设计与样本

  • 多中心平台试验,纳入可手术临床2或3期乳腺癌女性,原发肿瘤≥2.5 cm,无既往手术或系统治疗。
  • 排除ERBB2阴性/激素受体阳性且70基因检测低评分的肿瘤。
  • 2010年3月至2016年期间按分子亚型适应性随机分配至研究方案或对照治疗,分析截至2019年2月26日有随访数据的950例参与者。

主要发现

  • 950例参与者中位年龄49岁(范围23-77),330例(34.7%)达到pCR。
  • pCR者3年EFS和DRFS均为95%。
  • pCR对比非pCR的EFS风险比0.19(95%CI 0.12-0.31),DRFS风险比0.21(95%CI 0.13-0.34)。
  • 各分子亚型间风险比相似,EFS为0.14-0.18,DRFS为0.10-0.20。

临床怎么用

  • 新辅助治疗后达到pCR可作为高危可手术乳腺癌长期结局的强预后标志,支持将其用于风险分层和后续治疗决策参考。
  • pCR作为替代终点能否预测长期获益仍需进一步研究验证。

局限性

  • pCR是否为 validated surrogate(即改善pCR率可假定改善长期结局)尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. OBJECTIVE: To evaluate the association of pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS) in subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents. DESIGN, SETTING, AND PARTICIPANTS: Multicenter platform trial of women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger. Women with tumors that were ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score were excluded. Participants were adaptively randomized to one of several different investigational regimens or control therapy within molecular subtypes from March 2010 through 2016. The analysis included participants with follow-up data available as of February 26, 2019. INTERVENTIONS: Standard-of-care neoadjuvant therapy consisting of taxane treatment with or without (as control) one of several investigational agents or combinations followed by doxorubicin and cyclophosphamide. MAIN OUTCOMES AND MEASURES: Pathologic complete response and 3-year EFS and DRFS. RESULTS: Of the 950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR. Three-year EFS and DRFS for patients who achieved pCR were both 95%. Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. CONCLUSIONS AND RELEVANCE: The 3-year outcomes from the I-SPY2 trial show that, regardless of subtype and/or treatment regimen, including 9 novel therapeutic combinations, achieving pCR after neoadjuvant therapy implies approximately an 80% reduction in recurrence rate. The goal of the I-SPY2 trial is to rapidly identify investigational therapies that may improve pCR when validated in a phase 3 confirmatory trial. Whether pCR is a validated surrogate in the sense that a therapy that improves pCR rate can be assumed to also improve long-term outcome requires further study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01042379.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yee D, DeMichele AM, Yau C, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32701140. doi:10.1001/jamaoncol.2020.2535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。